Dorzolamide Hcl /timolol Maleate Solution/ Drops Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Dorzolamide HCI/Timolol Maleate Ophthalmic Solution contains Dorzolamide, a sulfonamide, and Timolol Maleate, a beta-adrenergic blocking agent; and although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides and/or systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of Timolol Maleate (see CONTRAINDICATIONS).
Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.
Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.
In Patients Without a History of Cardiac Failure continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, Dorzolamide HCl /Timolol Maleate Ophthalmic Solution should be discontinued.
Obstructive Pulmonary Disease
Patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution is contraindicated [see CONTRAINDICATIONS]) should, in general, not receive beta-blocking agents, including Dorzolamide HCl /Timolol Maleate.
The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures.
Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.
If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.
Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.
Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism.
Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Dorzolamide HCI/Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of Dorzolamide HCI/Timolol Maleate Ophthalmic Solution b.i.d. was slightly less than that seen with the concomitant administration of 0.5% Timolol b.i.d. and 2.0% Dorzolamide t.i.d. (see CLINICAL PHARMACOLOGY, Clinical Studies).
There is currently no drug history available for this drug.
Dorzolamide HCl /Timolol Maleate Ophthalmic Solution is the combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.
Dorzolamide Hydrochloride USP is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4Hthieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide Hydrochloride USP is optically active. The specific rotation is:
[α] 25°C (C=1, water) = ~ -17°.
Its empirical formula is C10H16N2O4S3•HCl and its structural formula is:
Dorzolamide Hydrochloride USP has a molecular weight of 360.91. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.
Timolol Maleate USP is described chemically as: (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol Maleate USP possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of Timolol Maleate USP is:
[α] 25°C in 1N HCl (C = 5) = –12.2° (–11.7° to –12.5°).
Its molecular formula is C13H24N4O3S•C4H4O4 and its structural formula is:
Timolol Maleate USP has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol Maleate USP is stable at room temperature.
Dorzolamide HCl /Timolol Maleate Ophthalmic Solution is supplied as a sterile, isotonic, buffered, slightly viscous, aqueous solution. The pH of the solution is approximately 5.65, and the osmolarity is 242-323 mOsM. Each mL of Dorzolamide HCl /Timolol Maleate contains 20 mg Dorzolamide (22.26 mg of Dorzolamide Hydrochloride) and 5 mg Timolol (6.83 mg Timolol Maleate). Inactive ingredients are Hydroxyethyl Cellulose, Mannitol, Sodium Citrate Dihydrate, Sodium Hydroxide, and Water for Injection.
Benzalkonium Chloride 0.0075% is added as a preservative.
Dorzolamide Hcl /timolol Maleate Solution/ Drops Manufacturers
Bausch & Lomb Incorporated
Login To Your Free Account